Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.
The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease.
It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.
The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 20, 23 | -0.60 Decreased by -93.55% | -0.12 Decreased by -400.00% |
| Aug 14, 23 | -0.33 Decreased by -94.12% | -0.25 Decreased by -32.00% |
| May 15, 23 | -0.77 Decreased by -20.31% | -0.28 Decreased by -175.00% |
| Mar 27, 23 | -0.54 Decreased by -74.19% | -0.37 Decreased by -45.95% |
| Nov 14, 22 | -0.31 Decreased by -34.78% | -0.68 Increased by +54.41% |
| Aug 15, 22 | -0.17 Increased by +26.09% | -0.57 Increased by +70.18% |
| May 16, 22 | -0.64 Decreased by -481.82% | -0.41 Decreased by -56.10% |
| Mar 2, 22 | -0.31 Increased by +38.00% | -0.01 Decreased by -3.00 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 371.79 K Increased by +N/A% | -14.73 M Decreased by -195.36% | Decreased by -3.96 K% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.09 M Decreased by -220.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -26.86 M Decreased by -192.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -11.24 M Decreased by -154.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.99 M Decreased by -52.38% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.53 M Increased by +21.67% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -9.18 M Decreased by -506.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 360.00 K Increased by +N/A% | -4.42 M Increased by +29.13% | Decreased by -1.23 K% Decreased by N/A% |